CELGENE CORPORATION for CELGENE CORPORATION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
- Corporate Tax Reform including House BluePrint.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK GLIHA | — |
| ERIN POLAK New | — |
Copyright/Patent/Trademark CPT
S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK GLIHA | — |
| ERIN POLAK | — |
| MATTHEW SCHUMAKER | — |
Health Issues HCR
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK GLIHA | — |
| ERIN POLAK New | — |
| MATTHEW SCHUMAKER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.